68832-50-8

Usage

Uses

Used in Pharmaceutical Industry:
3(R)-FLUORO-D-ASPARTIC ACID is used as a therapeutic agent for the treatment of cognitive function disorders and neurodegenerative diseases. Its agonistic action at the glutamate receptor suggests its potential in improving cognitive function and managing the progression of neurodegenerative conditions.
Used in Neuroscientific Research:
3(R)-FLUORO-D-ASPARTIC ACID is utilized as a research tool in neuroscientific studies to explore the mechanisms of neurotransmission and synaptic plasticity. Its effects on memory and learning provide insights into the development of new therapeutic strategies for cognitive enhancement.
Used in Drug Development:
3(R)-FLUORO-D-ASPARTIC ACID is employed as a lead compound in the development of new pharmaceuticals targeting cognitive impairments. Its demonstrated efficacy in preclinical studies makes it a promising candidate for further research and potential clinical applications in treating disorders that affect cognitive abilities.

Relevant academic research and scientific papers

THE SYNTHESIS OF 3-FLUOROASPARATIC ACID

A new synthesis of 3-flouroasparatic acid is based on the reaction of dibenzyl difluoromaleate (3) with dibenzylamine.Reduction of this product (4) with sodium cyanoborohydride gave dibenzyl 2-dibenzylamino-3-flurosuccinate (5), and thence hydrogenolysis

Potential carcinostatics. 4. Synthesis and biological properties of erythro- and threo-β-fluoroaspartic acid and erythro-β-fluoroasparagine

(E)- and (Z)-Di-tert-butyl 2-amino-3-fluoro-2-butene-1,4-dioate [(E)- and (Z)-2] were synthesized in two ways: (a) by elimination of hydrogen fluoride from di-tert-butyl β,β-difluoroasparatate under the influence of 1,5-diazabicyclo[4.3.0]non-5-ene and (b) by amination with the ammonium acetate of di-tert-butyl monofluorooxaloacetate (3), obtained via condensation of tert-butyl monofluoroacetate with di-tert-butyl oxalate. Reduction of 2 with sodium cyanoborohydride yielded a mixture of di-tert-butyl monofluoroaspartates in which the erythro isomer constituted the major product. The structure of this isomer (4a) was established by X-ray crystallographic analysis of the corresponding acid 5a. Esterification of 5a to the β-methyl ester 6, followed by aminolysis, yielded erythro-β-fluoroasparagine (7). Tests with 5a and 7 in the L-5178Y test system showed that the compounds exhibited toxicity at levels at which no antitumor activity was observed.